As a driver event in several cancers, ASXL1 status has been recognized as an inclusion criteria in cancer trials targeting hematological malignancies such as acute myeloid leukemia, myelodysplastic syndromes, acute myeloid leukemia arising from previous myelodysplastic syndrome, chronic myelomonocytic leukemia, and secondary acute myeloid leukemia [15]. This evidence concerns the gene ASXL1 and chronic myelomonocytic leukemia.